PALO ALTO, CA. April 25, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...
San Diego, CA and Palo Alto, CA., April 25, 2022 (GLOBE NEWSWIRE) – Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) today announced that Dr. Henry Ji, Chairman and CEO of Sorrento and Executive...
PALO ALTO, CA. April 12, 2022 /Newswire/ -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused...
ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States
PALO ALTO,...